Environmental Engineering Reference
In-Depth Information
59. Ahmad Y, Sharma N (2009) An effective method for the analysis of human plasma proteome
using two-dimensional gel electrophoresis. J Proteomics Bioinform 2:495-499
60. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA (2008) Nanoparticle size
and surface properties determine the protein corona with possible implications for biological
impacts. Proc Natl Acad Sci U S A 105(38):14265-14270
61. Gessner A, Lieske A, Paulke BR, Muller RH (2002) Influence of surface charge density on
protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis.
Eur J Pharm Biopharm 54:165-170
62. Gessner A, Lieske A, Paulke BR, Muller RH (2003) Functional groups on polystyrene model
nanoparticles: influence on protein adsorption. J Biomed Mater Res A 65A:319-326
63. Blunk T, Hochstrasser DF, Sanchez JC, Muller BW, Muller RH (1993) Colloidal carriers for
intravenous targeting: plasma protein adsorption patterns on surface modified latex particles
evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14:1382-
1387
64. Gessner A, Waicz R, Lieske A, Paulke BR, Mader K, Muller RH (2000) Nanoparticles with
decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm
196:245-249
65. Cedervall T, Lynch I, Foy M, Bergg T, Donnelly SC et al (2007) Detailed identification of
plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed 46:5754-5756
66. Cedervall T, Lynch I, Lindman S, Nilsson H, Thulin E, Linse S, Dawson KA (2007)
Understanding the nanoparticle-protein corona using methods to quantify exchange rates
and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A 104:2050-2055
67. L¨ck M, Schr¨der W, Paulke BR, Blunk T, M¨ ller RH (1999) Complement activation by
model drug carriers for intravenous application: determination by two-dimensional electro-
phoresis. Biomaterials 20:2063-2068
68. Leroux JC, Alleman E, de Jaeghere F, Doelker E, Gurny R (1996) Biodegradable
nanoparticles: from sustained release formulations to improved site specific drug delivery.
J Contr Release 39:339-350
69. Dobrovolskaia MA, Guszcysski T, Specht S, McLeland CB (2014) NCL method ITA-4—
analysis of nanoparticle interaction with plasma proteins by 2D PAGE, Available from:
http://ncl.cancer.gov/NCL_Method_ITA-4.pdf
.
Accessed on 09 July 2014
70. G¨ppert TM, M¨ ller RH (2005) Adsorption kinetics of plasma proteins on solid lipid
nanoparticles for drug targeting. Int J Pharm 302:172-186
71. G¨ppert TM, M¨ ller RH (2003) Plasma protein adsorption of Tween 80- and poloxamer
188-stabilized solid lipid nanoparticles. J Drug Target 11:225-231
72. G¨ppert TM, M¨ ller RH (2004) Alternative sample preparation prior to two-dimensional
electrophoresis protein analysis on solid lipid nanoparticles. Electrophoresis 25:134-140
73. Thode K, L¨ck M, Semmler W, M¨ ller RH, Kresse M (1997) Determination of plasma
protein adsorption on magnetic iron oxides: sample preparation. Pharm Res 14:905-910
74. Hanash S (2003) Disease proteomics. Nature 422:226-232
75. Rabilloud T (2002) Two-dimensional gel electrophoresis in proteomics: old, old fashioned,
but it still climbs up the mountains. Proteomics 2:3-10
76. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, BingGen R (2003) Use of serological proteomic
methods to find biomarkers associated with breast cancer. Proteomics 3:433-439
77. Charrier JP, Tournel C, Michel S et al (2001) Differential diagnosis of prostate cancer and
benign prostate hyperplasia using two dimensional electrophoresis. Electrophoresis 22:1861-
1866
78. Steel LF, Shumpert D, Trotter M et al (2003) A strategy for the comparative analysis of serum
proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3:601-
609
79. Kellner R, Lichtenfels R, Atkins D et al (2002) Targeting of tumor associated antigens in
renal cell carcinoma using proteome-based analysis and their clinical significance. Proteo-
mics 2:1743-1751
